Sunitinib and renal cell carcinoma Book Section
| Authors: | Motzer, R. J.; Hoosen, S. |
| Editors: | Davis, D. W.; Herbst, R. S.; Abbruzzese, J. L. |
| Article/Chapter Title: | Sunitinib and renal cell carcinoma |
| Abstract: | The majority of renal tumor malignancies are classified as renal cell carcinoma (RCC), which ranks 10th as the leading cause of cancer deaths, and constitutes 3% of all solid malignancies [1]. In the United States, approximately 31,000 new cases of RCC were predicted for 2005, leading to an estimated 12,000 deaths [2] and in Europe approximately 40,000 patients are newly diagnosed each year, leading to an estimated 20,000 deaths [3]. © 2008 by Taylor & Francis Group, LLC. |
| Book Title: | Antiangiogenic Cancer Therapy |
| ISBN: | 9781420004298 |
| Publisher: | CRC Press/Taylor & Francis Group |
| Publication Place: | Boca Raton, FL |
| Date Published: | 2008-01-01 |
| Start Page: | 807 |
| End Page: | 821 |
| Language: | English |
| DOI: | 10.1201/9781420004298 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 32 -- Export Date: 3 December 2018 -- Source: Scopus |
